Clinical trial · Observational
To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
A Retrospective Real-world Study in Patients With Nasopharyngeal Carcinoma: to Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
NCT04387266CI-TRIAL-00047610completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| modified reduce-volume target IMRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Modified reduce-volume target IMRT
- description
- Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT
- interventionNames
- Radiation: modified reduce-volume target IMRT
Primary outcomes (1)
- measure
- Local failure-free survival (LFFS)
- timeFrame
- 60 month
- description
- The duration of time to LFFS was calculated from the date of histological diagnosis until documented treatment local failure.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma; 2. Newly diagnosed, non-metastatic and treated with modified reduce-volume IMRT; 3. Patients with baseline MRI date of nasopharynx and neck, and completed the first course of treatment in our hospital; 4. Diagnosis time: November 1, 2014 to December 31 , 2017 Exclusion Criteria: 1. Disease progression during IMRT; 2. Previous malignancy or other concomitant malignant diseases; 3. The evaluation information of tumor efficacy can not be obtained; 4. Receive blind treatment in other clinical research.
References
Publications (0)
Data not yet available
No reference posted for this study.